Extensive-Stage Small Cell Lung Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Extensive-Stage Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Extensive-Stage Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Extensive-Stage Small Cell Lung Cancer Market.

The Extensive-Stage Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report: https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Extensive-Stage Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
• Extensive-Stage Small Cell Lung Cancer companies working in the treatment market are Shanghai Henlius Biotech, RayzeBio, Inc., Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others, are developing therapies for the Extensive-Stage Small Cell Lung Cancer treatment
• Emerging Extensive-Stage Small Cell Lung Cancer therapies in the different phases of clinical trials are- Serplulimab+Chemo, RYZ101, RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others are expected to have a significant impact on the Extensive-Stage Small Cell Lung Cancer market in the coming years.
• In November 2025, AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced the successful delivery of the first dose of Ariceum Therapeutics' (Ariceum) 225Ac-SSO110. This agent, a potentially first- and best-in-class Actinium-225-labeled antagonist of the somatostatin type 2 receptor (SSTR2), is under evaluation in Ariceum's Phase 1/2 SANTANA-225 clinical trial for treating extensive-stage small cell lung cancer (SCLC) and Merkel Cell Carcinoma (MCC). Through this partnership, AtomVie is utilizing its advanced cGMP facilities and technical expertise to ensure reliable manufacturing, securing a consistent supply and high-quality production of 225Ac-SSO110 to support the ongoing SANTANA-225 study.
• In September 2025, Merck reported positive findings from the Phase II IDeate-Lung01 trial (NCT05280470) assessing ifinatamab deruxtecan (I-DXd) in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). This potential first-in-class B7-H3-targeted DXd antibody-drug conjugate showed a confirmed objective response rate (ORR) of 48.2% among 137 patients, including 3 complete and 63 partial responses. The full study results were presented at the 2025 World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer.
• In September 2025, Results from a Phase II trial (NCT06449209) indicated that BioNTech's and Bristol Myers Squibb's (BMS) pumitamig (BNT327/BMS986545) exhibited promising anti-tumor activity in patients with extensive-stage small cell lung cancer (ES-SCLC). The companies noted that pumitamig could serve as a potential new treatment option for this aggressive lung cancer, offering hope for improved outcomes in a patient population with limited existing therapies.
• In August 2025, The FDA has granted Breakthrough Therapy Designation (BTD) to Merck's and Daiichi Sankyo's ifinatamab deruxtecan (I-DXd) for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy. This decision was based on data from the Phase II IDeate-Lung01 trial (NCT05280470), with additional support from the Phase I/II IDeate-PanTumor01 trial (NCT04145622). Complete results are scheduled to be presented in a late-breaking oral session at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
• In May 2024, Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for IMDELLTRATM (tarlatamab-dlle) to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy. This approval was expedited due to the promising response rate and duration of response (DoR) seen in clinical trials. Ongoing approval for this use may depend on further confirmation of clinical benefits in subsequent confirmatory trials.
• In May 2024, Genprex, Inc. has announced that the first patient with extensive-stage small cell lung cancer (ES-SCLC) has begun treatment with a combination of quaratusugene ozeplasmid (Reqorsa) and atezolizumab (Tecentriq) in the phase 1, dose-escalation part of the Acclaim-3 trial (NCT05703971). Acclaim-3 is an open-label, dose-escalation, phase 1/2 study designed to evaluate the clinical response of maintenance therapy using quaratusugene ozeplasmid alongside atezolizumab in patients with ES-SCLC.

Extensive-Stage Small Cell Lung Cancer Overview
Extensive-Stage Small Cell Lung Cancer (ESCLC) is a classification of small cell lung cancer (SCLC), which is a fast-growing type of lung cancer typically associated with heavy smoking. SCLC is divided into two stages: limited stage and extensive stage.

Get a Free Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Extensive-Stage Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
• Serplulimab+Chemo: Shanghai Henlius Biotech
• RYZ101: RayzeBio, Inc.
• RP12146: Rhizen Pharmaceuticals
• SYHA1807: CSPC ZhongQi Pharmaceutical Technology
• BNT411: BioNTech
• Bomedemstat: Imago BioSciences
• AK104: Akeso
• QL1706: Qilu Pharmaceutical Co
• Tarlatamab: Amgen
• Socazolimab: Sorrento Therapeutics
• Tislelizumab: BeiGen

Extensive-Stage Small Cell Lung Cancer Route of Administration
Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Extensive-Stage Small Cell Lung Cancer Molecule Type
Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment
• Extensive-Stage Small Cell Lung Cancer Assessment by Product Type
• Extensive-Stage Small Cell Lung Cancer By Stage and Product Type
• Extensive-Stage Small Cell Lung Cancer Assessment by Route of Administration
• Extensive-Stage Small Cell Lung Cancer By Stage and Route of Administration
• Extensive-Stage Small Cell Lung Cancer Assessment by Molecule Type
• Extensive-Stage Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight's Extensive-Stage Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Extensive-Stage Small Cell Lung Cancer product details are provided in the report. Download the Extensive-Stage Small Cell Lung Cancer pipeline report to learn more about the emerging Extensive-Stage Small Cell Lung Cancer therapies
https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Extensive-Stage Small Cell Lung Cancer Pipeline Analysis:
The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment.
• Extensive-Stage Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer drugs and therapies
https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Extensive-Stage Small Cell Lung Cancer Pipeline Market Drivers
• The rise in incidence rate of Extensive-Stage Small Cell Lung Cancer (ESCLC), iIncreasing Research and development are some of the important factors that are fueling the Extensive-Stage Small Cell Lung Cancer Market.

Extensive-Stage Small Cell Lung Cancer Pipeline Market Barriers
• However, high cost of the treatment, lack of awareness among the people for early detection of cancer and other factors are creating obstacles in the Extensive-Stage Small Cell Lung Cancer Market growth.

Scope of Extensive-Stage Small Cell Lung Cancer Pipeline Drug Insight
• Coverage: Global
• Key Extensive-Stage Small Cell Lung Cancer Companies: Shanghai Henlius Biotech, RayzeBio, Inc., Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others
• Key Extensive-Stage Small Cell Lung Cancer Therapies: Serplulimab+Chemo, RYZ101, RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others
• Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment: Extensive-Stage Small Cell Lung Cancer current marketed and Extensive-Stage Small Cell Lung Cancer emerging therapies
• Extensive-Stage Small Cell Lung Cancer Market Dynamics: Extensive-Stage Small Cell Lung Cancer market drivers and Extensive-Stage Small Cell Lung Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.